BiondVax to launch clinical trial for flu vaccine
"I am pleased to see our clinical program taking a significant step forward," BiondVax Chief Science Officer Tamar Ben-Yedidia.
The trial is to evaluate the immunogenicity and safety of BiondVax's universal influenza vaccine (Multimeric-001), followed by an administration of the H5N1 influenza vaccine. The trial subjects will be 222 healthy adults between the ages of 18 and 60. The trial will take place largely at a Budapest hospital, but also at other satellites throughout Hungary.
BiondVax is initiating the study to examine the benefits of priming with BiondVax's universal flu vaccine, which will allow public health officials to be prepared for flu pandemic outbreaks.
BiondVax has so far successfully completed five clinical trials (two Phase I/II and three Phase II), conducted with 479 participants for its Universal Flu Vaccine. The vaccine was found to be safe and effective.